A new study in The New England Journal of Medicine evaluates the efficacy of dupilumab, a drug being developed by Sanofi and Regeneron Pharmaceuticals, in patients with persistent, moderate-to-severe asthma and elevated eosinophil levels. “Three patients had an asthma exacerbation with dupilumab (6%)...